There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Daré Bioscience (DARE – Research Report), Legend Biotech (LEGN – Research Report) and Singular Genomics Systems (OMIC – Research Report) with bullish sentiments.
Daré Bioscience (DARE)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Daré Bioscience today and set a price target of $6.00. The company’s shares closed last Tuesday at $0.32, close to its 52-week low of $0.27.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
Currently, the analyst consensus on Daré Bioscience is a Moderate Buy with an average price target of $4.00, which is an 1190.3% upside from current levels. In a report released yesterday, Brookline Capital Markets also reiterated a Buy rating on the stock with a $3.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Legend Biotech (LEGN)
In a report issued on May 13, Yaron Werber from TD Cowen maintained a Buy rating on Legend Biotech, with a price target of $71.00. The company’s shares closed last Tuesday at $44.38, close to its 52-week low of $42.08.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $85.00, which is a 96.4% upside from current levels. In a report issued on May 13, RBC Capital also maintained a Buy rating on the stock with a $86.00 price target.
Singular Genomics Systems (OMIC)
TD Cowen analyst Daniel Brennan maintained a Buy rating on Singular Genomics Systems yesterday. The company’s shares closed last Tuesday at $0.43, close to its 52-week low of $0.31.
According to TipRanks.com, Brennan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Singular Genomics Systems with a $0.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DARE:
- Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
- DARE Earnings this Week: How Will it Perform?
- Biotech Alert: Searches spiking for these stocks today
- Dare Bioscience selected as spoke for ARPA-H Investor Catalyst Hub
- Daré Bioscience Secures Funding and Forges Royalty Agreements
